Omega Therapeutics, Inc. is a pharmaceutical company based in the United States that focuses on developing a new class of programmable epigenetic medicines called Omega Epigenomic Controllers. With an ESG score of 28.5, the company is considered to have a medium risk assessment. Omega Therapeutics aims to revolutionize human medicine by utilizing its proprietary epigenomic programming platform to selectively and directly control the human genome for the treatment and cure of diseases. Operating at the forefront of biotechnology, Omega Therapeutics is paving the way for sustainable and innovative healthcare solutions.